# Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

> **NCT02283658** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Ovarian Endometrioid Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Serous Surface Papillary Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Ovarian Carcinoma

## Interventions

- **DRUG:** Everolimus
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02283658
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-14
- **Primary completion:** 2016-06-15
- **Final completion:** 2018-06-21
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283658, "Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02283658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*